hATTR Amyloidosis Toolkit
The American Heart Association® (AHA) is leading an initiative to improve the identification and diagnosis of hereditary transthyretin amyloidosis (hATTR). This toolkit provides educational resources for accurate detection and diagnosis of hATTR amyloidosis, common misdiagnoses, the multidisciplinary teams involved, quality of life considerations for hATTR amyloidosis patients, and resources for genetic testing to confirm an hATTR amyloidosis diagnosis for patients and family members. The resources in this toolkit have been created and assembled by the AHA, its volunteer medical professionals from across the country, and the hospitals participating in this initiative. The materials are for educational purposes only. The content provided in the webinars does not constitute an endorsement or instruction by the American Heart Association or the American Stroke Association.
- hATTR Amyloidosis Quick Reference Guide (PDF): downloadable and printable reference guide that includes clinical clues and testing algorithms to promote earlier identification and accurate diagnosis of hATTR amyloidosis
- Genetic Testing Resource Cards (PDF): downloadable and printable cards for professionals to share with their patients with a QR code that links to information about TTR genetic testing
- Genetic Testing Tracking Tool (PDF): fillable tracking tool for patients or a family member to track who has received the genetic testing information
Alnylam Pharmaceuticals proudly sponsors the American Heart Association’s Quality Improvement Pilot for hATTR Amyloidosis Patients.